Moderna jumps after Phase 3 trial; Target slides

Earnings
โดย Investing.com·US·Read original
Summary · why it matters

Moderna shares jumped as much as 50% in premarket trading after the drugmaker and Merck said their experimental melanoma drug combination outperformed Keytruda alone in a Phase 3 trial. The INTerpath-001 study tested intismeran autogene, an investigational individualized mRNA-based neoantigen therapy, in combination with Merck's Keytruda in patients with completely resected stage IIB-IV melanoma, meeting its primary endpoint of recurrence-free survival and a key secondary endpoint measuring distant metastasis-free survival. Target stock fell 4.0% despite the retailer raising its annual sales forecast, with investors focusing on the impact of tariffs and the company's underlying profit outlook; comparable sales for the quarter ended Aug. 1 rose 3.8%, beating expectations for 2.5% growth, and tariff refunds provided a nearly $1 billion boost during the quarter. Honeywell Aerospace shares rose 2.8% after Morgan Stanley upgraded the newly independent aerospace company to Overweight from Equalweight and set a $205 price target, while Lowe's shares fell 2.6% after the home improvement retailer reported second-quarter results that beat expectations on earnings but missed badly on revenue. Estée Lauder rose 6.3% in premarket trading ahead of its fiscal fourth-quarter and full-year results, and Rising Dragon Acquisition Corp. surged 223.3% to $18.91 in premarket trading with no clear catalyst identified.

Impact on stocks 9

Biotech & Genomic Medicine▲ · 2 stocks
Moderna Inc
MRNA
▲ PositiveTechnologyrelevance

Moderna's experimental melanoma drug combination succeeded in Phase 3 trial.

Merck & Company Inc
MRK
▲ PositiveTechnologyrelevance

Merck's Keytruda combination with Moderna's therapy met primary endpoint in Phase 3 trial.

Consumer Staples▼ · 2 stocks
Target Corporation
TGT
▼ NegativeTariffrelevance

Investors focus on tariff impact and underlying profit outlook despite raised sales forecast.

Smart City / Autonomous Infrastructure▲ · 1 stocks
Consumer Discretionary▼ · 1 stocks
Defense & Geopolitical Fragmentation▲ · 1 stocks
Critical Materials & Supply Chain▲ · 1 stocks
Financials▲ · 1 stocks
© 2026 MarketDXNews